Margaret Boulton - ALLIANCE PHARMA Other - Medical and Regulatory Affairs Director

DVL Stock  EUR 0.39  0.01  2.50%   

Director

Margaret Boulton is Medical and Regulatory Affairs Director in Alliance Pharma Plc. Margaret joined Alliance in 2009. She has around twenty years of experience in the pharmaceutical and healthcare industries with RegulatoryScientific Affairs positions at Abbott Baxter and lan. Margaret graduated in Animal Science at Nottingham has a PhD from Edinburgh and an MBA from Bath. since 2014.
Tenure 10 years
Professional MarksMBA

Similar Executives

Showing other executives

DIRECTOR Age

Anthony BossoneWisdomTree Investments
47
Win NeugerWisdomTree Investments
68
John HendersonCDL INVESTMENT
N/A
Frank SalernoWisdomTree Investments
58
John LindsayCDL INVESTMENT
N/A
Brian SheaWisdomTree Investments
56
W YeoCDL INVESTMENT
45
Jason WeyenethWisdomTree Investments
N/A
Wee YeoCDL INVESTMENT
50
Tse LeeCDL INVESTMENT
67
Colin SimCDL INVESTMENT
N/A
Bruce LavineWisdomTree Investments
52
Susan CosgroveWisdomTree Investments
55
Kian TanCDL INVESTMENT
N/A
Steven BegleiterWisdomTree Investments
55
Jarrett LilienWisdomTree Investments
56
ALLIANCE PHARMA (DVL) is traded on Berlin Exchange in Germany and employs 13 people.

ALLIANCE PHARMA Leadership Team

Elected by the shareholders, the ALLIANCE PHARMA's board of directors comprises two types of representatives: ALLIANCE PHARMA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ALLIANCE. The board's role is to monitor ALLIANCE PHARMA's management team and ensure that shareholders' interests are well served. ALLIANCE PHARMA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ALLIANCE PHARMA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sarah Robinson, Company Secretary
David Cook, Independent Non-Executive Director
Janice Timberlake, Director of Human Resources
Andrew Franklin, Finance Director, Director
John Dawson, CEO, Executive Director
Stephen Kidner, Other - Operations Director
Dan Thomas, Other - Business Development Director
Anthony Booley, Executive Director
Andrew Smith, Non-Executive Director
Nigel Clifford, Independent Non-Executive Director
Margaret Boulton, Other - Medical and Regulatory Affairs Director
Thomas Casdagli, Non-Executive Director
Peter Butterfield, Executive Director

ALLIANCE Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ALLIANCE PHARMA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ALLIANCE PHARMA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ALLIANCE PHARMA's short interest history, or implied volatility extrapolated from ALLIANCE PHARMA options trading.

Pair Trading with ALLIANCE PHARMA

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ALLIANCE PHARMA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ALLIANCE PHARMA will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to ALLIANCE PHARMA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ALLIANCE PHARMA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ALLIANCE PHARMA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ALLIANCE PHARMA to buy it.
The correlation of ALLIANCE PHARMA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ALLIANCE PHARMA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ALLIANCE PHARMA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ALLIANCE PHARMA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ALLIANCE PHARMA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for ALLIANCE Stock analysis

When running ALLIANCE PHARMA's price analysis, check to measure ALLIANCE PHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ALLIANCE PHARMA is operating at the current time. Most of ALLIANCE PHARMA's value examination focuses on studying past and present price action to predict the probability of ALLIANCE PHARMA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ALLIANCE PHARMA's price. Additionally, you may evaluate how the addition of ALLIANCE PHARMA to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Bonds Directory
Find actively traded corporate debentures issued by US companies
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Please note, there is a significant difference between ALLIANCE PHARMA's value and its price as these two are different measures arrived at by different means. Investors typically determine if ALLIANCE PHARMA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ALLIANCE PHARMA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.